OncoMatch/Clinical Trials/NCT06680037
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
Is NCT06680037 recruiting? Yes, currently enrolling (Jul 2026). This Phase 1 trial studies Azercabtagene zapreleucel (azer-cel) for b-cell mediated autoimmune disorders.
Treatment: Azercabtagene zapreleucel (azer-cel) — The main objective of the study is to determine the recommended phase 2 dose (RP2D) of Azercabtagene zapreleucel (azer-cel).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Biomarker criteria
Required: AQP4 igg seropositive
Required: CHRNA1 antibody positive
Required: MUSK antibody positive
Demographics
Prior therapy
Cannot have received: adoptive T-cell therapy
Prior treatment with adoptive T-cell therapy or any gene therapy product directed at any target (e.g. CAR T-cell therapy)
Cannot have received: gene therapy
Prior treatment with adoptive T-cell therapy or any gene therapy product directed at any target (e.g. CAR T-cell therapy)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- TG Therapeutics Investigational Trial Site · La Jolla, California
- TG Therapeutics Investigational Trial Site · Ann Arbor, Michigan
- TG Therapeutics Investigational Trial Site · Omaha, Nebraska
- TG Therapeutics Investigational Trial Site · New York, New York
- TG Therapeutics Investigational Trial Site · Rochester, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06680037 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior adoptive T-cell therapy, gene therapy disqualifies patients from enrollment.
Does this trial require AQP4?
Yes, AQP4 igg seropositive is a required biomarker for enrollment.
Does this trial require CHRNA1?
Yes, CHRNA1 antibody positive is a required biomarker for enrollment.
Does this trial require MUSK?
Yes, MUSK antibody positive is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify